Precision for Medicine

A Phase 1-2 rare rheumatology program achieved all startup milestones ahead of schedule, enrolled eight healthy volunteer cohorts back-to-back on time, and navigated a fundamentally different enrollment landscape when transitioning to patients. The team managed this while adapting to frequent strategy changes and maintaining close sponsor governance across multiple geographies.

Designing Smarter Autoimmune Trials for Heterogeneity and Signal Detection Autoimmune diseases represent one of the most complex and heterogeneous areas for drug development, affecting hundreds of millions of patients worldwide. These conditions span a wide spectrum of clinical phenotypes, immunological drivers, and progression patterns. As therapeutic innovation accelerates—particularly with bio…

A small European biotech company required end ‑to ‑end regulatory, scientific and assay validation support to transform an exploratory IHC assay into a multi ‑indication, multi ‑region patient ‑selection tool across the US and Europe.

China’s Regulatory System Enters a New Phase of Modernization China’s pharmaceutical regulatory system is entering a new phase of accelerated modernization, creating policy driven opportunities for innovative drug development and global collaboration. The Fourth Revision of the Regulations for the Implementation of the Drug Administration Law , issued by the State Council in January 2026 and sche…

Early phase oncology research is often described as cutting edge. In practice, it is just as defined by logistics as by science. For Dr. Sankhala, the work of advancing new therapies has always been inseparable from a more practical question: how do patients outside large academic centers, who are often limited by cost, geography, or system barriers, gain timely access to clinical trials?

Choosing the right radiopharmaceutical CRO can make or break your clinical trial. When every minute counts, you need a partner who knows the stakes. Radiopharmaceutical clinical trials stand as some of the most complex studies in drug development today. These trials go beyond standard oncology studies, demanding strict adherence to specialized handling procedures, accommodating short half-life pr…

At NEXT Oncology, Dr. Tolcher has spent his career accelerating first-in-human cancer research. His perspective on what truly moves the field forward is simple. Work as one team. Remove friction. Meet patients where they are. The Precision Site Network is built to do exactly that.

As glo bal clinical development becomes more complex, China continues to play a critical role in scientific innovation, patient diversity, and biotech growth. Sponsors conducting global and multi regional clinical trials increasingly require partners who can operate with local precision while maintaining global consistency. To support this demand, Precision for Medicine has expanded its footprint…

Running a radiopharmaceutical clinical trial is a race against time It's a race in which even a minor delay can undermine patient schedules, imaging windows, and ultimately, data integrity. With some imaging agents carrying half‑lives measured in minutes, operational discipline becomes just as important as scientific rigor. And the stakes are only rising.

This is the story of how a monitoring only rescue team caught a silent PK problem before it damaged a Phase 1 CAR-T data package and persistent pattern recognition kept a complex trial on track. What first looked like a few isolated sample issues quickly resolved into a pattern: time sensitive PK samples were arriving invalid at one of the four participating sites in a rare population, first in h…

Why the EMA–FDA AI Principles Signal a New Era in Drug Development The EMA and FDA’s joint publication of 10 guiding principles for the use of AI across the medicines lifecycle marks an important moment for global drug development. These principles signal a clear step forward to help guide industry in terms of how sponsors design trials, manage data, and interact with regulators in both jurisdict…

In first‑line oncology, enrollment stalls when investigator confidence lags. This global Phase 3 trial shows how momentum is engineered.

Trends, Challenges, and Considerations Shaping Biomarker Development and Precision Medicine in 2026 and Beyond The integration of artificial intelligence (AI) and multi-omics technologies is reshaping translational research, offering new approaches to drug discovery and precision medicine. In this dynamic landscape, biotech and pharmaceutical organizations are faced with the question of how to ma…